Total Payments
$3,345
2024 Payments
$415.17
Companies
24
Transactions
71
Medicare Patients
7,950
Medicare Billing
$1.0M
Payment Breakdown by Category
Food & Beverage$3,333 (99.6%)
Education$12.45 (0.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,333 | 70 | 99.6% |
| Education | $12.45 | 1 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $409.61 | 7 | $0 (2024) |
| GlaxoSmithKline, LLC. | $329.68 | 3 | $0 (2019) |
| Edwards Lifesciences Corporation | $302.94 | 2 | $0 (2019) |
| BOSTON SCIENTIFIC CORPORATION | $270.53 | 4 | $0 (2018) |
| Mylan Specialty L.P. | $220.00 | 2 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $189.93 | 2 | $0 (2018) |
| Allergan Inc. | $184.49 | 12 | $0 (2018) |
| Amgen Inc. | $164.24 | 5 | $0 (2019) |
| Kowa Pharmaceuticals America, Inc. | $163.12 | 5 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $154.89 | 5 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $415.17 | 4 | Janssen Pharmaceuticals, Inc ($140.29) |
| 2023 | $252.44 | 3 | Janssen Pharmaceuticals, Inc ($117.14) |
| 2022 | $220.12 | 2 | Medtronic, Inc. ($110.12) |
| 2019 | $727.36 | 18 | Edwards Lifesciences Corporation ($146.66) |
| 2018 | $1,292 | 22 | GlaxoSmithKline, LLC. ($221.30) |
| 2017 | $438.16 | 22 | BOSTON SCIENTIFIC CORPORATION ($126.77) |
All Payment Transactions
71 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/16/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $110.00 | General |
| Category: Cardiology | ||||||
| 03/27/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $140.29 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 02/20/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $54.88 | General |
| Category: Diabetes | ||||||
| 01/04/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $110.00 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 10/06/2023 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $25.30 | General |
| Category: Cardiology | ||||||
| 09/21/2023 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $117.14 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/21/2023 | Mylan Specialty L.P. | Yupelri (Drug) | Food and Beverage | In-kind items and services | $110.00 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 12/03/2022 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $110.00 | General |
| Category: INSOMNIA | ||||||
| 09/20/2022 | Medtronic, Inc. | ONYX FRONTIER (Device) | Food and Beverage | In-kind items and services | $110.12 | General |
| Category: Stents | ||||||
| 11/19/2019 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/13/2019 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $12.53 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 11/06/2019 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $92.95 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/23/2019 | Janssen Pharmaceuticals, Inc | INVOKANA (Drug) | Food and Beverage | In-kind items and services | $97.00 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 10/16/2019 | Regeneron Healthcare Solutions, Inc. | PRALUENT (Biological) | Food and Beverage | In-kind items and services | $12.73 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 09/05/2019 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $12.94 | General |
| Category: Cardiology | ||||||
| 07/25/2019 | PFIZER INC. | ELIQUIS (Drug), VYNDAQEL | Food and Beverage | In-kind items and services | $12.67 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 06/25/2019 | GlaxoSmithKline, LLC. | ANORO (Drug) | Food and Beverage | In-kind items and services | $108.38 | General |
| Category: RESPIRATORY | ||||||
| 06/19/2019 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $110.00 | General |
| Category: Neuroscience | ||||||
| 06/18/2019 | Regeneron Healthcare Solutions, Inc. | PRALUENT (Biological) | Food and Beverage | In-kind items and services | $12.97 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 04/26/2019 | Kowa Pharmaceuticals America, Inc. | Livalo (Drug), Bystolic | Food and Beverage | Cash or cash equivalent | $10.82 | General |
| Category: Cardiovascular | ||||||
| 04/03/2019 | Edwards Lifesciences Corporation | Edwards SAPIEN 3 Ultra Transcatheter Heart Valve (Device) | Food and Beverage | In-kind items and services | $146.66 | General |
| Category: Transcatheter Heart Valves | ||||||
| 03/28/2019 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $12.78 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/21/2019 | Kowa Pharmaceuticals America, Inc. | Livalo (Drug), Bystolic | Food and Beverage | Cash or cash equivalent | $10.89 | General |
| Category: Cardiovascular | ||||||
| 02/08/2019 | PFIZER INC. | CHANTIX (Drug), ELIQUIS | Food and Beverage | In-kind items and services | $16.15 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 02/05/2019 | Regeneron Healthcare Solutions, Inc. | PRALUENT (Biological) | Food and Beverage | In-kind items and services | $17.74 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 2,242 | 3,442 | $1.0M | $280,165 |
| 2022 | 10 | 2,167 | 3,439 | $1.0M | $291,913 |
| 2021 | 11 | 1,843 | 3,106 | $861,497 | $255,057 |
| 2020 | 11 | 1,698 | 2,939 | $785,645 | $218,196 |
Total Patients
7,950
Total Services
12,926
Medicare Billing
$1.0M
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 218 | 220 | $293,348 | $82,407 | 28.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 397 | 717 | $210,762 | $67,873 | 32.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 267 | 277 | $157,253 | $39,827 | 25.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 188 | 188 | $83,622 | $25,264 | 30.2% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 109 | 440 | $62,251 | $18,813 | 30.2% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 210 | 421 | $102,000 | $13,565 | 13.3% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 229 | 231 | $44,849 | $11,839 | 26.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 490 | 808 | $37,677 | $9,201 | 24.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 45 | 48 | $18,888 | $6,927 | 36.7% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 13 | 16 | $12,080 | $3,358 | 27.8% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 30 | 30 | $2,023 | $634.50 | 31.4% |
| 93246 | Heart rhythm recording of continous external ekg over 8-15 days | Office | 2023 | 35 | 35 | $1,167 | $347.81 | 29.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 11 | 11 | $418.00 | $107.10 | 25.6% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2022 | 236 | 236 | $314,682 | $93,797 | 29.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 363 | 670 | $196,947 | $64,974 | 33.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 284 | 296 | $168,039 | $44,686 | 26.6% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2022 | 128 | 506 | $71,589 | $24,425 | 34.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 157 | 157 | $69,834 | $20,970 | 30.0% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2022 | 228 | 453 | $108,720 | $13,803 | 12.7% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2022 | 258 | 262 | $50,867 | $13,638 | 26.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 466 | 808 | $37,677 | $9,426 | 25.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 30 | 34 | $13,379 | $5,173 | 38.7% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2022 | 17 | 17 | $4,165 | $1,020 | 24.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 370 | 714 | $209,880 | $70,558 | 33.6% |
| 78452 | Nuclear medicine study of vessels of heart using drugs or exercise multiple studies | Office | 2021 | 167 | 167 | $222,678 | $70,496 | 31.7% |
About Dr. Amit Mittal, MD
Dr. Amit Mittal, MD is a Cardiovascular Disease healthcare provider based in Northport, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/18/2007. The National Provider Identifier (NPI) number assigned to this provider is 1134324494.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amit Mittal, MD has received a total of $3,345 in payments from pharmaceutical and medical device companies, with $415.17 received in 2024. These payments were reported across 71 transactions from 24 companies. The most common payment nature is "Food and Beverage" ($3,333).
As a Medicare-enrolled provider, Mittal has provided services to 7,950 Medicare beneficiaries, totaling 12,926 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Northport, NY
- Active Since 06/18/2007
- Last Updated 07/08/2007
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1134324494
Products in Payments
- XARELTO (Drug) $312.61
- Livalo (Drug) $163.12
- Edwards SAPIEN 3 Transcatheter Heart Valve (Device) $156.28
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve (Device) $146.66
- NUCALA (Biological) $122.59
- Saxenda (Drug) $120.06
- BYSTOLIC (Drug) $117.49
- ONYX FRONTIER (Device) $110.12
- Aimovig (Biological) $110.00
- QUVIVIQ (Drug) $110.00
- UPTRAVI (Drug) $110.00
- YUPELRI (Drug) $110.00
- Yupelri (Drug) $110.00
- ANORO (Drug) $108.38
- Xyrem (Drug) $106.87
- ELIQUIS (Drug) $106.17
- TRELEGY ELLIPTA (Drug) $98.71
- INVOKANA (Drug) $97.00
- FARXIGA (Drug) $92.95
- OFEV (Drug) $90.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.